Twist Bioscience Respiratory Virus Research Panel
Twist Bioscience has launched the Twist Respiratory Virus Research Panel, a next-generation sequencing approach to detecting 29 common human respiratory viruses including SARS-CoV-2, several other coronaviruses, influenzas, rhinoviruses, and respiratory syncytial virus. The research-use-only panel will be bundled with an analysis platform from One Codex to enable a complete workflow beginning with Twist's target enrichment panel and ending with publication-ready visuals, the company said. The panel includes RNA- and DNA-based viruses in one kit with 41,047 nucleic acid probes, can detect as little as 100 copies of viral material, and has coverage of greater than 99.9 percent of the genome at 1X or greater post-enrichment.
NeoGenomics Liquid Biopsy Assays
NeoGenomics announced the launch of three new liquid biopsy products for advanced non-small cell lung cancer, all solid tumor types, and breast cancer.
The InVisionFirst-Lung liquid biopsy assay tests 37 genes related to the care of advanced NSCLC and covers all National Comprehensive Cancer Network guideline-recommended genomic drivers with targeted therapies for NSCLC. NeoGenomics partnered with Inivata to commercialize the test.
The NeoLab Solid Tumor Liquid Biopsy is a next-generation sequencing test for genomic profiling of solid tumors. The test is part of the NeoLab suite of assays providing biomarker evaluation for patients with hematologic diseases who can't have a bone marrow biopsy and whose peripheral blood counts are low.
The Qiagen Therascreen PIK3CA RGQ PCR kit is a companion diagnostic approved by the US Food and Drug Administration for use with alpelisib (Novartis' Piqray) that detects 11 clinically actionable mutations in the PIK3CA gene. NeoGenomics will launch the test in situations where PIK3CA testing can't be performed using tumor tissue due to insufficient samples, low quantities of tumor cells, or tissue sample decalcification.
Flagship Biosciences TissueInsight
Flagship Biosciences has launched a new clinical diagnostics immuno-oncology service called TissueInsight, which provides CLIA-reportable PD-L1 results along with data about a tumor's microenvironment to pathologists, oncologists, and immunologists to aid them in optimizing care for cancer patients. According to the company, users of the service follow their normal IHC slide staining process, then scan the slides and send the images to Flagship, which analyzes them with their proprietary image-analysis process. TissueInsight gives rapid, data-rich tissue interpretation and removes the inherent variability of subjective manual tissue scoring, the company said. Along with its CLIA-reportable results, TissueInsight tumor microenvironment data includes information on tumor infiltrating lymphocytes and macrophages, the company added.
For more new products and services, please visit the New Products page on our website.